Neural cell adhesion molecules (NCAMs) are found predominantly in neural, muscle and endocrine cells. Recent interest has focused on their potential role in tumorigenesis. We have analysed the expression and secretion of NCAM in a series of 48 human pituitary adenomas. Immunocytochemical analysis of 19 adenomas demonstrated NCAM expression in all tumours with, in each case, diffuse cytoplasmic staining being found with variable membrane accentuation. There were no apparent differences in the expression of immunoreactivity seen on sections between individual tumours. Cell culture media from 43 dispersed human pituitary tumours were analysed by immunoassay for the secretion of soluble NCAM and all the pituitary hormones. In contrast to the immunocytochemical studies, soluble NCAM was released from only 27% of human pituitary tumours, but this was not related to tumour type nor was the amount of soluble NCAM released correlated with the amount of pituitary hormone secreted by each adenoma. NCAM expression is common to all human pituitary adenoma types and the observed differences in release of soluble NCAM between individual tumours may reflect different molecular mechanisms, altering adhesive interactions between normal and adenomatous tissue.
INTRODUCTION
Neural cell adhesion molecules (NCAMs) are a family of sialoglycoprotein molecules that are involved in intercellular adhesion and found predominantly in neural, muscle and endocrine cells.I Cell--eell interactions mediated by molecules such as NCAM are thought to playa key role in embryogenesis and development, and thus altered expression of cell adhesion molecules may be important in turnorigenesis.?
Three major protein isoforms of NCAM with molecular masses of 180, 140 and 120 kDa have been characterized; they are generated from a single gene by alternative splicing. The two larger isoforms are membrane-spanning with large and small cytoplasmic domains, respectively; the 120-kDa isoform of NCAM is anchored to the membrane by a phosphatidyl-Correspondence: Prof. J M Burrin. E-mail: j.m.burrin@mds.qmw.ac.uk 660 inositol linkage. Soluble forms of NCAM are found in conditioned culture media from neural and muscle cells and in serum of patients with small-cell lung cancer.' It is not clear whether these soluble forms of NCAM are released from the plasma membrane by protease and/or phospholipase activity, or whether they originate by direct secretion into the extracellular milieu. The significance of the presence of these distinct forms ofNCAM is not fully understood, but they may be important for modulating NCAM-mediated cell adhesion.
Human pituitary adenomas are regarded primarily as benign lesions and cases of pituitary tumours associated with metastases are rare. However, a high proportion of pituitary adenomas may display a locally aggressive behaviour, compressing local structures such as the optic chiasm, eroding bone and extending into or invading the sphenoidal or cavernous sinuses. Local invasiveness is likely to be partly the result of altered interactions between the tumorous cells and extracellular matrix adhesive proteins such as the integrins and cell adhesion molecules."
The aims of the present study were to examine NCAM expression by immunocytochemistry in human pituitary adenomas of all types, measure soluble NCAM release from a large series of human adenomatous pituitaries in cell culture and establish whether qualitative or quantitative differences in the expression and secretion of NCAM in adenomas are associated with their hormone secretory characteristics.
MATERIALS AND METHODS
Pituitary tumours (n = 48) were collected in the operating room at the time of transsphenoidal adenomectomy. Tissues were prepared for histological studies for tumour diagnosis, and the remaining portions of each tumour were collected aseptically for tissue culture. The tumour type was determined on the basis of clinical and biochemical findings before surgery, morphological and immunocytochemical findings, and in vitro cell culture studies.
Pituitary adenoma tissue was transported to the laboratory in Dulbecco's modified Eagle's medium containing 10% (v/v) heat-inactivated fetal calf serum, 0·06 giL penicillin, 0·1 giL streptomycin and 2·5 g/L fungi zone (GIBCO-BRL, Paisley, Strathclyde, UK) and buffered with HEPES (0'02 mol/L), hereafter referred to as culture medium. Tumour tissue was dispersed enzymatically with trypsin as described previously" and washed in medium, and dispersed cells were plated in 24-well plates at approximately 2 x lOS cells per well in 2 mL of medium. Cultures were incubated for 48 h to allow cell attachment to occur, after which time the medium was collected. Approximately five to ten individual cultures were obtained from each tumour. All pituitary hormones, including pituitary glycoprotein hormone IX-subunit (IXSU), were measured in media as described previously.' Between-batch precision for all these hormone assays is less than 14%. All samples from each individual tumour were analysed in the same assay. All hormone data are expressed as hormone amount secreted per 24 h per 10 6 cells.
The cell culture media from 43 pituitary tumours were also assayed for NCAM using an enzyme immunoassay essentially as described previously.' This assay uses two antibodies, NCC-LU-246 and NCC-LU-243 (Nippon Kayaku, Tokyo, Japan), which recognize distinct epitopes on the NCAM molecule. Standard curves were generated from serial dilutions in culture medium of NCAM extracted from human meningioma tissue. Human meningioma tissue was lysed in phosphate-buffered saline (PBS), pH 7-4,2 mmol/L phenylmethanesulphonyl fluoride (PMSF) and 1% (v/v) Triton X-100. Extracts were centrifuged at 1500g for 10 min and aliquots of the supernatant stored at -20°C for no longer than 6 weeks. A fresh aliquot of extract supernatant was used for standardization of each assay and all cell culture media were assayed within the 6-week time period. Unconditioned culture medium was used as an internal blank in each assay. Internal controls were analysed in each assay and the inter-assay variation was less than 9%.
For histological examination, the tissue was fixed in 10% formolasaline and processed into paraffin wax. Sections of all tumours were studied with haematoxylin and eosin, reticulin and periodic acid-Schiff stains. Routine immunostaining was performed for growth hormone (GH), prolactin (PRL), adrenocorticotrophic hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH; antibodies against the whole molecule obtained from Biogenex Ltd, Berks, UK) and the common IX-subunit of pituitary glycoprotein hormones (IXSU; rabbit polyclonal, UCB Bioproducts, Braine-L'Alleud, Belgium) using a standard streptavidin-biotinhorseradish peroxidase method.
Nineteen pituitary adenomas from the total series of 48 were stained for NCAM. Immunocytochemical staining using a 60-min incubation with the monoclonal antibody NCC-LU-243 (Nippon Kayaku, Tokyo, Japan) at a dilution of 1:800 was performed on these tumours by means of a standard streptavidinbiotin-horseradish peroxidase method. Antigen retrieval was carried out in a microwave run at full power (950 W). Sections were placed in 0·01 mol/L citric acid buffer, boiled for 10 min and then left standing in hot buffer for a further 5 min. Sections for positive control were taken from a cerebral neuroblastoma and from the meningioma that had been used for preparation of the standard for the NCAM immunoassay (see above). Sections for negative control were treated exactly as the test sections, except that the primary antibody was omitted.
Statistical analysis Spearman correlation coefficients were calculated to examine the relationship between amounts of soluble NCAM and pituitary hormones released in culture. Non-parametric analysis was preferred since the distribution of amounts of NCAM did not approximate to a normal distribution. Fisher's exact test (STAT-XACT-Turbo) was used to calculate two-tailed P values for comparison of the frequency of soluble NCAM positivity between different types of adenoma.
RESULTS

NCAM and pituitary hormone release in vitro
A summary of the amounts of NCAM released according to tumour type is shown in Fig. I . Fifteen of the 21 clinically non-functioning tumours studied had no detectable pituitary hormone expression, as assessed by immunocytochemistry or pituitary hormone release in culture, and were thus described as null cell adenomas, but five of these released NCAM. The remaining six clinically non-functioning adenomas were 'silent' gonadotroph tumours of which two released detectable amounts of soluble NCAM. Of the 10 somatotroph tumours studied, all released GH and seven released 2500 variable amounts of other hormones; NCAM was detected in the media from only two somatotroph tumours. Nine corticotroph tumours were studied, all of which released ACTH; in only three of these was NCAM detected in the media. None of the three prolactinomas studied released NCAM. In the total series of 43 pituitary adenomas for which soluble NCAM was measured, there was no correlation between NCAM released and the amounts of any of the seven other pituitary hormones secreted in culture (Table I) . When soluble NCAM was considered as present ( + ve) or absent (ve), the frequency of NCAM positivity did not differ significantly amongst the tumour types (.1'('(' Table 2 ).
Immunocytochemical expression of NCAM NCAM was expressed by the positive control tumours (a cerebral neuroblastoma and a meningioma) and all the 19 pituitary adenomas studied (nine null cell, three gonadotroph, four somatotroph, two corticotroph and one pro lactinoma). In all cases except one, the cytoplasm of the adenoma cells was diffusely stained, with variable membrane accentuation (Fig. 2) examined by immunocytochemistry were also screened for soluble NCAM release by immunoassay. Despite all 14 adenomas staining for NCAM, only six of these tumours had detectable levels of soluble NCAM in their culture media. There was no apparent correlation between the amount of soluble NCAM released and the amount of NCAM expression detected immunocytochemically.
DISCUSSION
The present study clearly documents, by immunocytochemical analysis, NCAM expression in human pituitary adenomas of all types. Soluble NCAM release was evident from a proportion (27%) of cultured pituitary tumours, although this was not correlated to tumour type or hormone secretory profiles. Our study is the largest series of pituitary adenomas reported so far and the only study to document soluble NCAM release. However, other studies are required to confirm these findings as the number of tumours positive for NCAM release is still small.
Three previous studies have documented NCAM expression in human pituitary adenomas." K Jin et al.' showed NCAM expression by immunohistochemical and in situ hybridization analysis in four null cell adenomas, a prolactinoma and three normal pituitaries. NCAM immunoreactivity has also been observed by electron microscopy in four prolactinomas, three somatotrophs and four inactive adenomas." A later study on a larger series (n = 20) of null cell. plurihormonal, weak gonadotrophic macroadenomas, growth hormone-prolactin adenomas and prolactinomas showed immunostaining for NCAM in either a cytoplasmic, peripheral membranous or mixed pattern." There was no correlation between NCAM staining pattern and invasive characteristics of the tumours, suggesting that NCAM expressivity was not a useful marker for assessing pituitary tumour invasiveness. We also found diffuse cytoplasmic staining, with variable membrane accentuation, in all pituitary adenomas studied, with the exception of the only prolactinoma studied. There were no significant differences in either the pattern or intensity of staining between the different tumour types, except in the paleness of the cytoplasmic staining in the prolactinoma. Interestingly, corticotroph tumours which, to our knowledge, have not been previously studied, showed a similar intensity and pattern of staining to the other tumour types. The corticotroph tumours in our study were predominantly microadenomas. In contrast to corticotroph macroadenomas, these tumours are generally regarded as non-invasive. Thus, the results from our study would support those of earlier reports that NCAM expression is not a useful marker for tumour type or invasiveness.
Our study is the first to provide evidence that some human pituitary adenomatous cells produce a secreted isoform of NCAM. Soluble forms of NCAM have been found in conditioned culture medium from neural and muscle cells, and in a variety of body fluids including the serum of patients with small cell lung cancer." In the latter study, there was a suggestion that serum NCAM activity may be related to disease activity. We found no correlation between the amount of soluble NCAM detected and the tumour type, although secreted NCAM was absent in the three prolactinomas studied. Aletsee-Ufrecht et al. 6 also noted low levels of expression of NCAM in prolactinomas by immunoblotting, and Kleinschmidt-DeMasters et al. s showed only patchy immunostaining in two out of three prolactinomas. Thus, the absence of NCAM in prolactinomas may be of some significance.
There was no apparent correlation between the amount of soluble NCAM released by the cultured pituitary tumours and the degree of immunoreactivity seen on sections. The secreted isoform of NCAM is thought to be generated by alternative splicing of the human NCAM gene, and thus represents a different structural isoform to the membrane-associated isoforms. The antibodies we used for immunocytochemical staining and for immunoassay are well char-Ann Clin Biochem 1999: 36 acterized as so-called cluster-l antibodies, and detect the major membrane-associated NCAM isoforms and the soluble NCAM isoform.l Thus, until antibodies directed against the different isoforms are developed, it remains unclear whether NCAM detected by immunocytochemistry is structurally identical to secreted NCAM or represents the membrane-associated isoforms. It seems more likely that, in those pituitary adenomas that secrete NCAM, a posttranscriptional event has occurred, resulting in the expression of the structurally distinct isoform of soluble NCAM. The factors that might regulate this alternative splicing are not well understood and in our hands do not appear to relate to the amounts of any of the seven pituitary hormones secreted by the adenomas.
In summary, immunocytochemical analysis of human pituitary tumours has demonstrated the presence of NCAM in all tissues examined with no detectable differences between the tumour types. Of the pituitary tumours cultured in vitro, 27% released soluble NCAM, but again there were no apparent quantitative or qualitative differences between the different types of tumour or their pituitary hormone secretory profiles. The molecular mechanisms underlying the secretion of soluble NCAM by some pituitary tumours require further investigation.
